Royalty Pharma SG&A Expenses 2019-2024 | RPRX

Royalty Pharma sg&a expenses for the twelve months ending June 30, 2024 were $0.229B, a 11.07% decline year-over-year.

  • Royalty Pharma annual sg&a expenses for 2023 were $0.25B, a 9.87% increase from 2022.
  • Royalty Pharma annual sg&a expenses for 2022 were $0.227B, a 24.33% increase from 2021.
  • Royalty Pharma annual sg&a expenses for 2021 were $0.183B, a 0.61% increase from 2020.

Royalty Pharma SG&A Expenses 2019-2024 | RPRX

  • Royalty Pharma annual sg&a expenses for 2023 were $0.25B, a 9.87% increase from 2022.
  • Royalty Pharma annual sg&a expenses for 2022 were $0.227B, a 24.33% increase from 2021.
  • Royalty Pharma annual sg&a expenses for 2021 were $0.183B, a 0.61% increase from 2020.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$188.7B
Blackstone (BX)$111.6B
Moody's (MCO)$87.9B
Orix Corp Ads (IX)$27.5B
Grupo Financiero Banorte SAB De CV (GBOOY)$21.2B
Brookfield Asset Management (BAM)$20.2B
Synchrony Financial (SYF)$19.4B
Equitable Holdings (EQH)$13.2B
Jefferies Financial Group (JEF)$12.5B
Houlihan Lokey (HLI)$11.1B
Daiwa Securities Group (DSEEY)$11B
XP (XP)$10.8B
Globe Life (GL)$9.5B
SouthState (SSB)$7.5B
Brookfield Wealth Solutions (BNT)$7.3B
Jackson Financial (JXN)$6.5B
StepStone Group (STEP)$6B
Rithm Capital (RITM)$5.7B
Blue Owl Capital (OBDC)$5.7B
Lazard (LAZ)$5.6B
Freedom Holding (FRHC)$5.6B
Virtu Financial (VIRT)$5B
Euronet Worldwide (EEFT)$4.5B
HA Sustainable Infrastructure Capital (HASI)$4.1B
AXOS FINANCIAL, INC (AX)$3.7B
Abrdn (SLFPY)$3.5B
PJT Partners (PJT)$3.1B
Community Financial System (CBU)$3.1B
Core Scientific (CORZ)$3B
StoneX Group (SNEX)$2.6B